Progress development of the GSK245 (DDD1305143) compound for leishmaniasis.
current phase of drug development
updated 3 Jul 2023
In April 2017, DNDi and GSK entered into an agreement for the pre-clinical development of two compounds for leishmaniasis: GSK245 (formerly GSK245/DDD1305143) and DNDi-6899 (formerly GSK899/DDD853651). The compounds were developed through a collaboration between the GSK Global Health Unit and the Drug Discovery Unit at the University of Dundee, with co-funding support from Wellcome. In February 2020, DNDi and GSK signed a development and license agreement for GSK245 (DDD1305143).
Get our latest news, personal stories, research articles, and job opportunities.